Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH), concludes a ...

Newswise — MINNEAPOLIS, July 11, 2023 /PRNewswire/ -- Urotronic, Inc. today announced it has received U.S. Food and Drug Administration (FDA) approval of its Optilume ® BPH Catheter System, a unique ...

August 10, 2023 – Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH) ...

Newswise — MINNEAPOLIS, July 18, 2023 /PRNewswire/ -- Urotronic, Inc., a Minnesota-based medical device company pioneering the application of its drug-coated balloon technologies for use in ...

A non-ablative treatment for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) achieved durable improvement in urinary symptoms and flow rate, according to data from three ...

Dr. Steven A. Kaplan presented positive 4-year and 12-month clinical outcomes during the American Urological Association's Annual Meeting "The positive data from the PINNACLE and EVEREST trials – ...

LAS VEGAS -- A novel, non-ablative intervention for lower urinary tract symptoms (LUTS) produced rapid, durable symptom relief with no adverse effect on sexual function, long-term results from ...

Study demonstrates Optilume BPH treatment results in significant improvements immediately post procedure through one year; highest reported Qmax in BPH MIST trials MINNEAPOLIS, Aug. 30, 2023 ...

PORTSMOUTH, N.H., Oct. 28, 2024 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp (Laborie), announced today that the American Medical ...

Dr. Steven A. Kaplan presented positive 4-year and 12-month clinical outcomes during the American Urological Association's Annual Meeting MINNEAPOLIS, May 1, 2023 /PRNewswire/ -- Urotronic, Inc., a ...